Octreotide and lanreotide are the two long-acting somatostatin analogues sold in the United States as monthly depot injections. They are close relatives: both are synthetic eight-amino-acid peptides modelled on somatostatin, and both act mainly on the same receptor. What each one is, in its own entry, is set out in Peptide Lexicon's octreotide and lanreotide pages. This page compares what matters when the two are set side by side: what the FDA has approved each for, how each is given, and what their trials actually measured. Nothing here is a recommendation; the choice between them belongs to the treating specialist.
What each label covers
The two labels overlap on acromegaly and diverge on tumours.
| Octreotide (Sandostatin LAR Depot) | Lanreotide (Somatuline Depot) | |
|---|---|---|
| First US approval of the molecule | 1988 | 2007 |
| Acromegaly | Yes — long-term maintenance, in patients who responded to short-acting octreotide | Yes — long-term treatment after inadequate response to, or no option for, surgery or radiotherapy |
| Tumour growth (progression-free survival) | No. The label states the effect on tumour size, growth and metastases "has not been determined" | Yes — unresectable, well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs) |
| Carcinoid syndrome symptoms | Yes — severe diarrhoea and flushing of metastatic carcinoid tumours | Yes — reduces use of short-acting rescue octreotide |
| VIPomas | Yes — profuse watery diarrhoea | Not on the label |
| Label read | Sandostatin LAR Depot, Novartis, DailyMed listing 23 December 2025 | Somatuline Depot, Ipsen, DailyMed listing 17 October 2024 |
The single biggest label difference is the tumour-growth row. It is not a statement that octreotide does not slow these tumours; it reflects which manufacturer took which trial to the FDA. That trial history is the next section.
How each is given
The two depots are prepared and injected differently, which is part of why clinics treat them as separate products.
| Octreotide LAR | Lanreotide depot | |
|---|---|---|
| Form | Powder mixed with diluent, injected immediately | Ready-filled syringe holding a gel |
| Route | Into the gluteal muscle; the label says never under the skin or into a vein | Deep under the skin, upper outer buttock |
| Who gives it | A trained healthcare provider | A healthcare provider (the label's wording) |
| Interval on the label | Every 4 weeks; longer intervals not recommended | Every 4 weeks |
| Strengths on the label | 10, 20 and 30 mg kits; acromegaly doses up to 40 mg | 60, 90 and 120 mg syringes |
| Prerequisite on the label | A prior response to, and tolerance of, short-acting octreotide | None stated |
| Half-life figure the label gives | 1.7 hours for short-acting octreotide; the depot spreads release over the month | 23 to 30 days for the depot |
The labels' acromegaly schedules are built the same way: a fixed starting dose for three months, then adjustment by growth hormone and IGF-1 results. The milligram figures are not comparable across the two drugs, because the molecules and release systems differ. An oral form of octreotide, Mycapssa, also exists; its label limits it to acromegaly maintenance in people who have already responded to octreotide or lanreotide injections.
The tumour-growth trials: PROMID and CLARINET
Each drug has one placebo-controlled trial showing slower tumour growth. They are often quoted together as if they were two arms of one study. They were not.
| PROMID (octreotide LAR) | CLARINET (lanreotide) | |
|---|---|---|
| Published | Rinke et al., J Clin Oncol, 2009 | Caplin et al., N Engl J Med, 2014 |
| Patients | 85 at the planned interim analysis | 204 |
| Tumours | Well-differentiated metastatic midgut tumours only; functioning and non-functioning | Pancreas (45%), midgut (35%), hindgut (7%), unknown (13%); non-functioning only |
| Prior treatment | Treatment-naive | 14% had prior chemotherapy |
| Dose | 30 mg into muscle monthly | 120 mg deep under the skin every 28 days, up to 96 weeks |
| Primary end point | Time to tumour progression | Progression-free survival (progression or death), central radiology review |
| Result | Median 14.3 months vs 6 months; hazard ratio 0.34 (0.20 to 0.59) | 32 of 101 vs 60 of 103 events; hazard ratio 0.47 (0.30 to 0.73); 24-month progression-free rate 65.1% vs 33.0% |
| Overall survival | Not confirmatory (7 vs 9 deaths) | No significant difference |
Three things follow from the table. First, the hazard ratios cannot be ranked against each other: PROMID's lower figure comes from a smaller, midgut-only, treatment-naive group measured on a different end point. Second, CLARINET's patients were mostly stable before they entered — the NEJM paper reports 96% had no progression in the 3 to 6 months before randomisation — which matters when reading how much the drug added. Third, CLARINET carried the pancreatic tumours that PROMID excluded, and it was the trial submitted to the FDA, which is why only lanreotide's label carries the indication.
Both trials were placebo-controlled. CLARINET was funded by Ipsen, lanreotide's maker. PROMID was led by investigators at Philipps University in Marburg, Germany; its funding is not stated in the abstract and was not checked for this page.
What head-to-head evidence exists
Direct comparisons are few, small, or built on a product that is no longer the one sold.
- Chanson et al., 2000 (Clin Endocrinol; 125 acromegaly patients). Patients on lanreotide SR 30 mg, an older formulation injected every 10 or 14 days, were switched to octreotide LAR 20 mg monthly. After three months, normal IGF-1 rose from 48% to 65%. The first author's listed affiliation is Novartis, octreotide's maker, and the comparator was not Somatuline Depot.
- Tutuncu et al., 2012 (Pituitary; 68 patients after incomplete pituitary surgery). A retrospective analysis found "biochemical cure" in 63.9% on octreotide LAR and 78.1% on lanreotide, a difference that was not statistically significant (p = 0.454), with similar tumour shrinkage.
- Salvatori et al., 2026 (J Clin Endocrinol Metab; network meta-analysis of 18 randomised trials). Biochemical control rates were comparable across long-acting injectable somatostatin analogues, including lanreotide depot and octreotide LAR. This is an indirect comparison, and the analysis was funded by Crinetics, which makes a competing oral drug.
No head-to-head trial has compared the two current depots on tumour growth.
Side effects, in one line each
The two labels list the same families of effect — gallstones and biliary sludge, slower heart rate, high or low blood sugar, reduced thyroid function, diarrhoea, abdominal pain and fat malabsorption — because they act on the same receptor. In CLARINET, diarrhoea judged treatment-related occurred in 26% on lanreotide and 9% on placebo, and 5% of lanreotide patients stopped for adverse reactions against 3% on placebo (the Somatuline label). The Sandostatin label's own figures, including biliary abnormalities in 63% of trial patients, are set out on octreotide side effects. For how these effects compare with the rest of the approved peptide class, see FDA-approved peptides.
What is not established
- Which drug slows tumours more. There is no trial that answers it; the two placebo-controlled trials differ in patients, size and end point.
- Whether octreotide's US label will gain a tumour-growth indication. The PROMID result has been published since 2009, but the current US label does not carry it.
- Long-term comparative safety. Neither label compares its rates with the other's, and the labels warn that rates from different trials cannot be compared directly.
Who makes the decision
Which analogue, at what dose and whether to switch are decisions for the endocrinologist or oncologist treating the person. This page reports the labels and trials and does not replace them.
Sources and dates
- Sandostatin LAR Depot (octreotide acetate) kit, Novartis, US prescribing information, DailyMed, listed 23 December 2025 — sections 1, 2, 12 and 14. Read 10 November 2026.
- Somatuline Depot (lanreotide) injection, Ipsen, US prescribing information, DailyMed, listed 17 October 2024 — sections 1, 2, 6.1, 12 and 14. Read 10 November 2026.
- Mycapssa (octreotide) delayed-release capsules, DailyMed, listed 28 July 2025 — indication only.
- Generic depot listings read on DailyMed, 10 November 2026: octreotide acetate for injectable suspension (Mylan Institutional, Teva); lanreotide injection (Cipla, Amneal, Exelan).
- Rinke A et al. J Clin Oncol 2009;27(28):4656–63. PMID 19704057.
- Caplin ME et al. N Engl J Med 2014;371(3):224–33. PMID 25014687.
- Chanson P et al. Clin Endocrinol (Oxf) 2000;53(5):577–86. PMID 11106918.
- Tutuncu Y et al. Pituitary 2012;15(3):398–404. PMID 21863263.
- Salvatori R et al. J Clin Endocrinol Metab 2026;111(6):1786–99. PMID 41773305.
